Effectiveness of HIV Pre-Exposure Prophylaxis (PrEP): A Meta-Analysis of 100 Studies (2000–2025)
Description
This document presents a comprehensive meta-analysis of 100 studies published between 2000 and 2025 on the effectiveness of HIV pre-exposure prophylaxis (PrEP). It synthesizes findings from randomized controlled trials and observational studies across diverse populations, including MSM, serodiscordant couples, people who inject drugs, and high-risk heterosexuals. The analysis highlights adherence as the most critical factor influencing PrEP efficacy, evaluates safety outcomes, and compares oral versus injectable PrEP regimens. Results confirm that PrEP is a safe, effective, and essential component of global HIV prevention strategies. Policy recommendations emphasize adherence support, equitable access, and integration into primary healthcare systems.
Files
Steps to reproduce
Here are the key highlights of your PrEP meta-analysis (2000–2025): • ✅ Strong effectiveness: PrEP significantly reduces HIV risk, with the highest protection seen in MSM (90%) and serodiscordant couples (75%). • ✅ Adherence is critical: The level of protection is directly tied to how consistently people take PrEP. • ✅ Injectable PrEP is promising: Long-acting cabotegravir shows efficacy comparable to oral PrEP and may help improve adherence. • ✅ Safety profile is favorable: Most side effects (GI issues, mild renal changes, injection site reactions) were mild and reversible. • ✅ Population gaps: Data on transgender people and adolescents remain limited and need more research. • ✅ Global relevance: The findings support scaling up PrEP programs as a core HIV prevention strategy, especially in high-risk groups.